RACHENGOLD-WERK ADOLF SPECK – Trademark Portfolio

Entity Type: 13

RACHENGOLD-WERK ADOLF SPECK holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. The portfolio also extends into Class 30 (Staple Foods) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include VELAMINTS. The owner is based in KARLSRUHE/BADEN.

KARLSRUHE/BADEN , DE

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

RACHENGOLD-WERK ADOLF SPECK's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (7 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

30
Staple Foods (7 filings)

Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations

Frequently Asked Questions

How many trademarks does RACHENGOLD-WERK ADOLF SPECK have?

RACHENGOLD-WERK ADOLF SPECK has 9 U.S. trademarks filed with the USPTO. Of these, 1 registered, 8 cancelled.

What trademark classes does RACHENGOLD-WERK ADOLF SPECK file in?

RACHENGOLD-WERK ADOLF SPECK files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 30 (Staple Foods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are RACHENGOLD-WERK ADOLF SPECK's most well-known trademarks?

RACHENGOLD-WERK ADOLF SPECK's registered trademark portfolio includes well-known marks such as VELAMINTS. These are among 1 currently registered trademark in the portfolio.

What is RACHENGOLD-WERK ADOLF SPECK's trademark registration success rate?

RACHENGOLD-WERK ADOLF SPECK has a 11% trademark registration rate, with 1 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.